Overall, the research indicates a growing understanding of the JAK/STAT signaling pathways involved in alopecia areata, which has led to the development of targeted therapies. The success of these ...

For far too long, patients with alopecia areata have gone without a licensed treatment option available via NHS pathways. 'If new treatments are only available privately, it becomes a case of the ...

These pathways have allowed health care providers to identify medicines that can work to treat alopecia areata. Olumiant contains the medicine baricitinib, which helps calm the overactive ...

patients with alopecia areata have gone without a licensed treatment option available via NHS pathways. "If new treatments are only available privately, it becomes a case of the 'haves and the ...

Having asthma, Hashimoto’s thyroiditis or atopic dermatitis in addition to alopecia areata raised the odds for early-onset, severe and prolonged alopecia areata, according to a research letter ...

Their results have now been published in the journal "Allergy". Alopecia areata (AA) is a common autoimmune disease that leads to sudden circular hair loss. The clinical course of AA is ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

successfully conducting our Phase 2a clinical trial in alopecia areata for AQST-108, 4) continuing to expand our sales of Libervant® (diazepam) Buccal Film for patients between two to five years ...